obsolete_incontinentia pigmenti achromians: a dermal melanocytic condition affecting the shoulder area. Nevus of Ito often occurs in association with nevus of Ota in the same patient but is much less common, although the true incidence is unknown.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
164 |
4. Check minimum number of eventsNone |
164 |
5. Include endpointsNone |
164 |
6. Filter based on genotype QC (FinnGen only) |
148 |
Control definitions (FinnGen only)
- Control exclude
- L12_OTHERSKINSUBCUTIS
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L81
- Name in latin
- Chloasma
Similar endpoints
↥List of similar endpoints to
Chloasma
based on the number of shared cases.
Similar with more cases:
- Other disorders of pigmentation
- Other disorders of skin and subcutaneous tissue
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 918 | 754 | 148 |
| Only index persons | 851 | 720 | 131 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.00 |
| Only index persons | 0.02 | 0.03 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 47.29 | 48.22 | 43.92 |
| Only index persons | 47.24 | 48.03 | 42.87 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 148 | 126 | 22 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.01 |
| Median age at first event (years) | 48.96 | 49.66 | 44.94 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 164
- Matched controls
- 1640
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L81.1
ICD-10 Finland
Chloasma
+∞
191.2
144
*
L82
ICD-10 Finland
Seborrhoeic keratosis
3.4
10.1
45
165
L57.0
ICD-10 Finland
Actinic keratosis
4.0
9.6
31
91
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.9
9.2
63
294
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.3
8.6
24
63
L81.4
ICD-10 Finland
Other melanin hyperpigmentation
94.7
8.5
9
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
8.5
52
227
D48.5
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Skin
4.4
7.6
20
50
7090A
ICD-9 Finland
Other disorders of skin and subcutaneous tissue, Dyschromia[CHLOASMA]
+∞
7.3
7
*
D10AX03
ATC
azelaic acid; topical
3.5
6.6
24
76
L30.9
ICD-10 Finland
Dermatitis, unspecified
2.7
6.5
40
173
QAA05
NOMESCO Finland
Incision for biopsy of skin of head or neck
15.1
6.5
10
7
70901
ICD-8 Finland
Other diseases of skin, Chloasma symptomaticum aliud sive NUD
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
14
43
3.47
4.01
1.3
1.3
287.29
314.75
ug/g
—
7
23
105
785
1.94
3.95
8.9
9.0
3.73
3.96
e9/l
0.74
95
689
65
420
1.91
3.79
1.8
2.3
55.59
55.47
u/l
0.01
59
381
64
427
1.82
3.29
4.5
2.8
—
—
—
0
0
93
701
1.75
3.10
5.1
5.4
9.17
9.85
umol/l
0.56
86
657
52
333
1.82
3.01
1.5
1.2
0.58
1.52
u/ml
0.86
13
90
74
527
1.74
2.98
2.2
1.8
101.91
97.58
pmol/l
0.37
41
259
84
633
1.67
2.66
6.6
5.6
1.24
1.22
mmol/l
1.69
74
535
87
665
1.66
2.59
3.7
3.3
0.00
0.00
estimate
-0.00
17
112
17
77
2.35
2.47
1.0
1.1
—
—
—
0
0
85
658
1.61
2.32
5.1
4.6
0.00
0.00
estimate
-0.00
17
118
24
129
2.01
2.32
1.6
1.6
—
—
—
0
0
8
23
3.60
2.30
1.3
1.8
—
—
—
0
0
6
13
4.75
2.29
1.5
1.3
—
—
—
0
0
6
13
4.75
2.29
1.5
1.3
—
—
—
0
0
48
326
1.67
2.19
2.2
2.6
587.37
921.70
ng/l
1.27
39
272
95
762
1.59
2.19
3.1
3.6
6.10
6.42
mmol/l
0.91
88
686
84
655
1.58
2.18
3.7
3.3
0.00
0.00
estimate
-0.00
19
129
19
97
2.08
2.10
1.7
1.5
—
—
—
0
0
31
188
1.80
2.10
1.5
1.7
—
—
—
0
0
123
1058
1.65
2.04
4.8
3.8
10.96
11.17
mm/h
0.09
117
977
64
476
1.57
2.00
2.3
3.0
12.58
34.85
ng/l
1.57
35
308
156
1458
2.43
1.96
16.6
13.3
71.10
70.85
umol/l
0.06
156
1458
15
73
2.16
1.87
1.5
1.4
—
—
—
0
0
5
12
4.26
1.83
2.2
1.9
4.94
3.87
nmol/l
—
5
12
29
180
1.74
1.82
2.9
2.8
2.78
2.97
e6/l
0.03
19
90
22
126
1.86
1.79
1.6
1.6
—
—
—
0
0
44
307
1.59
1.78
1.8
2.0
—
—
—
0
0
126
1106
1.60
1.76
4.3
4.1
14.22
14.60
pmol/l
1.17
117
1019
72
563
1.50
1.74
15.2
10.4
1.23
1.19
inr
0.14
25
165
7
24
3.00
1.74
2.0
1.2
—
—
—
0
0
7
24
3.00
1.74
2.0
1.2
—
—
—
0
0
19
105
1.92
1.71
2.7
2.2
61.64
67.72
ml/min/173m2
0.34
11
40
78
627
1.47
1.61
2.3
2.3
—
—
—
0
0
11
50
2.29
1.61
2.3
1.6
—
—
—
0
0
19
109
1.84
1.54
3.2
6.2
105.26
104.30
mmol/l
0.47
19
109
35
239
1.59
1.54
3.5
3.1
33.96
268.17
ng/l
1.31
23
163
12
58
2.15
1.53
2.3
1.4
—
—
—
0
0
73
584
1.45
1.53
5.5
4.6
1.24
1.22
mmol/l
1.62
64
524
16
87
1.93
1.52
1.6
1.4
—
—
—
0
0
79
647
1.43
1.43
2.7
2.7
85.59
78.77
ug/l
0.24
74
598
9
41
2.26
1.39
1.2
1.3
—
—
—
0
0
35
246
1.54
1.37
2.6
2.5
2.43
2.44
mmol/l
0.31
29
220
9
42
2.21
1.36
1.8
2.8
25.71
24.40
mmol/l
—
9
42
107
939
1.40
1.23
3.2
3.3
—
—
—
0
0
8
39
2.10
1.17
2.9
3.5
39.63
53.00
%
—
8
39
59
474
1.38
1.15
3.4
3.0
2.35
2.36
mmol/l
0.10
49
421
148
1389
1.67
1.14
15.2
11.4
17.37
19.29
mg/l
0.33
127
1059
22
145
1.60
1.13
6.0
4.8
—
—
—
0
0
63
513
1.37
1.13
3.8
3.2
—
—
—
0
0
141
1312
1.53
1.09
5.6
4.8
1.95
1.81
mu/l
0.88
136
1203
5
22
2.31
1.04
1.0
1.5
—
—
—
0
0
9
47
1.97
1.04
2.2
1.7
—
—
—
0
0
140
1307
1.49
0.99
13.6
11.0
83.19
83.09
ml/min/173m2
0.02
121
1054
7
36
1.99
0.98
1.4
1.4
—
—
—
0
0
144
1355
1.51
0.94
4.9
4.2
5.73
5.79
mmol/l
0.14
137
1251
26
188
1.46
0.90
2.7
2.6
1.16
0.84
e6/l
0.21
17
98
136
1270
1.42
0.89
5.3
5.0
37.89
38.94
mmol/mol
0.99
130
1183
8
45
1.82
0.85
2.5
1.9
—
—
—
0
0
6
31
1.97
0.85
1.5
1.1
—
—
—
0
0
40
316
1.35
0.85
1.5
1.5
18.78
22.00
nmol/l
0.89
34
266
42
335
1.34
0.84
1.8
1.5
—
—
—
0
0
20
142
1.47
0.77
2.8
3.9
3.13
10.20
ug/l
1.28
15
110
5
25
2.03
0.73
1.6
1.2
—
—
—
0
0
147
1403
1.46
0.73
5.3
4.7
2.99
2.86
mmol/l
0.96
142
1294
5
27
1.88
0.69
1.0
1.1
—
—
—
0
0
11
70
1.61
0.67
1.5
1.6
—
—
—
0
0
42
348
1.28
0.64
3.8
3.4
0.00
0.00
estimate
-0.00
17
118
8
49
1.66
0.63
1.0
1.8
—
—
—
0
0
8
49
1.66
0.63
2.8
2.3
1.05
0.93
%
—
8
49
8
50
1.63
0.62
1.0
1.8
—
—
—
0
0
5
30
1.69
0.62
1.0
1.2
—
5.27
—
0
11
41
341
1.27
0.61
3.2
2.7
0.10
0.58
e6/l
1.96
34
255
38
313
1.28
0.61
1.7
1.6
0.72
1.07
mg/l
1.03
30
246
16
115
1.43
0.59
4.7
4.1
18.94
21.47
%
—
7
47
8
54
1.51
0.58
2.0
1.2
—
—
—
0
0
12
82
1.50
0.56
1.3
1.3
32.13
27.17
iu/l
0.18
12
74
16
117
1.41
0.54
2.6
3.4
201.75
239.01
u/l
1.83
16
111
19
144
1.36
0.53
6.5
4.8
2.01
1.81
ug/l
0.09
19
126
143
1373
1.32
0.53
4.8
4.2
1.50
1.56
mmol/l
1.15
138
1271
33
272
1.27
0.53
1.6
1.3
12.07
32.06
iu/ml
—
6
98
45
392
1.20
0.44
1.7
1.6
1.38
1.37
mmol/l
0.03
39
334
12
88
1.39
0.41
3.0
3.0
0.73
0.69
ug/l
—
5
53
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
11
144
0.75
0.35
1.9
1.6
—
—
—
0
0
6
82
0.72
0.24
1.0
1.5
—
—
—
0
0
5
37
1.36
0.24
1.0
1.2
—
—
—
0
0
5
38
1.33
0.23
1.2
1.3
—
—
—
0
0
20
172
1.19
0.23
1.4
1.9
—
—
—
0
0
35
317
1.13
0.22
2.8
2.4
323.33
4158.94
umol/l
1.31
30
277
0
11
0.00
0.21
0.0
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
12
0.00
0.21
0.0
2.8
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.4
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
6
51
1.18
0.19
2.3
7.6
24.33
24.59
mmol/l
—
6
51
18
159
1.15
0.16
1.3
1.8
—
—
—
0
0
7
89
0.78
0.15
1.4
1.3
—
—
—
0
0
8
98
0.81
0.14
2.9
3.7
1.24
1.23
mmol/l
—
8
83
135
1329
1.09
0.11
4.3
3.7
1.22
1.23
mmol/l
0.04
129
1219
38
360
1.07
0.10
4.6
3.4
2.16
9.00
mg/mmol
2.28
18
203
5
47
1.07
0.09
2.0
1.6
—
—
—
0
0
6
56
1.07
0.09
1.0
1.8
35.67
39.35
u/l
—
6
50
13
117
1.12
0.08
1.3
1.2
89.57
172.60
iu/ml
—
7
53
28
266
1.06
0.06
1.6
1.2
18.73
6.45
u/ml
0.30
12
105
28
293
0.95
0.05
1.5
1.5
—
—
—
0
0
16
164
0.97
0.00
1.7
1.4
1.48
1.32
%
0.62
11
136
12
123
0.97
0.00
3.0
3.2
—
—
—
0
0
20
197
1.02
0.00
2.3
2.4
0.85
0.81
mmol/l
0.68
20
186
0
7
0.00
-0.00
0.0
1.3
—
34.01
—
0
7
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
5.7
—
213.83
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
7.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
500.40
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.3
—
—
—
0
0
6
68
0.88
-0.00
2.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
185.43
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint L12_CHLOASMA and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have L12_CHLOASMA.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: L12_CHLOASMA – Chloasma
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data